Healthcare / BiotechnologyNasdaqCM
$2.26
-0.04 (-1.74%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-8.1M · quality 52.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
10/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$8M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-210.0%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2025 · 15 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.93x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-8.8M · FCF $-8.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||
| Revenue | — | — | — | — | — | — | — | $39.9M | $43.0M | $48.6M | $36.1M | $20.3M | — | — | — | — | — |
| Net Income | $-8.8M | $-8.8M | $-9.6M | $-17.3M | $-18.5M | $-49.0M | $-6.9M | $-2.4M | $-16.9M | $-9.1M | $-2.8M | $-814075.00 | $-33644.00 | $-161.00 | $-24621.00 | $-33380.00 | $-39441.00 |
| EBITDA | $-8.6M | $-8.6M | $-9.3M | $-17.9M | $-19.5M | $-64.0M | $-5.5M | $-31237.00 | $-4.2M | $-7.7M | $-4.0M | $-627774.00 | — | — | — | — | — |
| EPS | -36.24 | -36.24 | -228.48 | -1455.48 | -195.00 | -279963.00 | — | -1528200.00 | -11053800.00 | -10125000.00 | -2835000.00 | -945000.00 | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | 20.4% | 20.9% | 21.1% | 19.2% | 33.9% | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | -5.8% | -16.6% | -22.4% | -14.9% | -3.9% | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — | — | -6.0% | -39.3% | -18.7% | -7.7% | -4.0% | — | — | — | — | — |
| Balance Sheet | |||||||||||||||||
| Debt/Equity | — | — | — | — | 0.00 | — | — | -0.41 | 0.00 | 0.06 | 0.13 | — | — | — | — | — | — |
| Current Ratio | 11.67 | 11.67 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||
| Free Cash Flow | $-8.1M | $-8.1M | $-7.7M | $-14.1M | $-17.7M | $-11.6M | — | — | — | — | — | — | — | — | — | — | — |
| Returns | |||||||||||||||||
| ROE | -210.0% | -210.0% | -601.1% | -884.9% | -126.1% | -219.6% | -201.0% | 133.1% | 25815.9% | -46.7% | -23.8% | -314.9% | 869.1% | 0.8% | 122.7% | -732.8% | 79.7% |
| Valuation | |||||||||||||||||
| P/B | 0.18 | 0.18 | 344.40 | 252.29 | 48.61 | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||
| Revenue Growth | — | — | — | — | — | — | — | -7.2% | -11.5% | 34.4% | 78.4% | — | — | — | — | — | — |
| EPS Growth | 84.1% | 84.1% | 84.3% | -646.4% | — | — | — | 86.2% | -9.2% | -257.1% | -200.0% | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-84.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-228.48 → -36.24
Residual
-84.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.